⌕
Arcutis Biotherapeutics · ARQT · Nasdaq
Tenet 43 · Weak
Compare
$27.33+0.66%At closeTenet 43 · Weak
$27.33+0.18 (+0.66%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Arcutis Biotherapeutics (ARQT) Stock

Arcutis Biotherapeutics (ARQT) closed at $27.33 on Nov 17, 2026; its Tenet Score is 43 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

14 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$27.33
Nov 17, 2026
Market cap
$3.4B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
124.2×
TTM through Sep 30, 2026 · as of close, Nov 16, 2026
52-week range
19.30 – 34.80
low → high · as of close, Nov 16, 2026
Tenet Score
43/100
Weak · 340 Healthcare peers

Industry: Drugs

Arcutis Biotherapeutics Inc scores 43/100. Weak. Strongest on quality, value is the soft spot, trading at 124× earnings versus 340 Healthcare peers. Insufficient inputs: Tenet 43 is built from 3 of 4 pillars, from 90% of its inputs. Growth is left out because no growth rate could be measured.

Tenet Score · vs sector

n=340
43/ 100
Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
9
Quality
68
Health
51
Growth
—

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
ValueFQualityCHealthCGrowth—MomentumC
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
14.1×
Sep 30, 2026 balance sheet
P/S
6.7×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
15%
TTM through Sep 30, 2026
Operating margin
−3.3%
fiscal 2025, before interest and tax
Net margin
5.9%
TTM through Sep 30, 2026
Current ratio
2.92
Sep 30, 2026 balance sheet
Net debt / EBITDA
−4.1×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Arcutis Biotherapeutics Inc

Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 100 US ETFs · top wrappers by weightSee all ETFs holding ARQT →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Arcutis Biotherapeutics in?

Arcutis Biotherapeutics is in the Healthcare sector and the Drugs industry.

What is Arcutis Biotherapeutics' Tenet Score?

Arcutis Biotherapeutics' Tenet Score is 43 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.